Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer

Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.

Inclusion Criteria:

• Aged 75 years or less
• Adenocarcinoma of stomach
• Advanced, metastatic, or recurrent
• No prio chemotherapy for advanced disease
• Adequate performance status
• Adequate major organ functions

Exclusion Criteria:

• Severe comorbid illness or active infections
• Pregnancy or lactating women
• GI obstruction or malabsorption syndrome